MPM Oncology Impact Management

Latest statistics and disclosures from MPM Oncology Impact Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are RPTX, TCRR, HARP, Iteos Therapeutics, EPZM, and represent 72.37% of MPM Oncology Impact Management's stock portfolio.
  • Added to shares of these 2 stocks: Iteos Therapeutics (+$58M), EPZM (+$6.2M).
  • Started 1 new stock positions in Iteos Therapeutics.
  • MPM Oncology Impact Management was a net buyer of stock by $64M.
  • MPM Oncology Impact Management has $415M in assets under management (AUM), dropping by 10.35%.

Tip: Access up to 7 years of quarterly data

Positions held by MPM Oncology Impact Management LP consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for MPM Oncology Impact Management

Companies in the MPM Oncology Impact Management portfolio as of the September 2020 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Repare Therapeutics Common (RPTX) 17.7 $74M 2.4M 30.77
TCR2 Therapeutics Common (TCRR) 16.5 $69M 3.4M 20.32
Harpoon Therapeutics Common (HARP) 16.0 $66M 3.9M 16.99
iTeos Therapeutics Common 14.0 $58M NEW 2.4M 24.67
Epizyme Common (EPZM) 8.2 $34M +22% 2.9M 11.93
MEI Pharma Common 7.6 $32M 10M 3.12
Turning Point Therapeutics Common (TPTX) 6.5 $27M 309k 87.36
ADC Therapeutics Common (ADCT) 4.3 $18M 540k 32.99
G1 Therapeutics Common (GTHX) 4.0 $16M 1.4M 11.55
YmAbs Therapeutics Common (YMAB) 3.1 $13M 337k 38.39
Merus Common (MRUS) 2.0 $8.4M 701k 12.00
Autolus Therapeutics Common (AUTL) 0.1 $463k 40k 11.65

Past Filings by MPM Oncology Impact Management

SEC 13F filings are viewable for MPM Oncology Impact Management going back to 2019